Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-547 in Healthy Volunteers and Psoriasis
NCT07232004Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2025
- Primary completion
- May 2028
- Countries
- 2
01
Overview
Phase 1, randomised trial of ABBV-547 in psoriasis (11 arms), sponsored by AbbVie Inc. Primary endpoint: Adverse Events at Day 365. Started Nov 2025; status: active, not recruiting.
02
Drugs
ABBV-547
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT07232004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232004.